uniQure (NASDAQ:QURE) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of uniQure (NASDAQ:QURE) have been given a consensus rating of “Moderate Buy” by the seven brokerages that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $32.00.

Several analysts recently commented on QURE shares. StockNews.com upgraded shares of uniQure to a “sell” rating in a research note on Friday, March 1st. Mizuho reduced their price objective on shares of uniQure from $10.00 to $7.00 and set a “neutral” rating for the company in a research note on Monday, March 4th. The Goldman Sachs Group cut shares of uniQure from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $63.00 to $8.00 in a research note on Thursday, February 29th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 price objective on shares of uniQure in a research note on Wednesday, December 20th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $28.00 price objective on shares of uniQure in a research note on Tuesday, January 16th.

Insider Buying and Selling at uniQure

In other uniQure news, COO Pierre Caloz sold 9,455 shares of the firm’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $6.47, for a total transaction of $61,173.85. Following the completion of the transaction, the chief operating officer now directly owns 85,643 shares in the company, valued at approximately $554,110.21. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, COO Pierre Caloz sold 9,455 shares of uniQure stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $6.47, for a total transaction of $61,173.85. Following the completion of the sale, the chief operating officer now directly owns 85,643 shares in the company, valued at $554,110.21. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Matthew C. Kapusta sold 27,904 shares of uniQure stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $6.35, for a total transaction of $177,190.40. Following the sale, the chief executive officer now owns 440,839 shares of the company’s stock, valued at $2,799,327.65. The disclosure for this sale can be found here. In the last three months, insiders sold 53,265 shares of company stock worth $339,845. 4.05% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On uniQure

A number of hedge funds and other institutional investors have recently modified their holdings of QURE. Citigroup Inc. grew its holdings in uniQure by 667.9% in the third quarter. Citigroup Inc. now owns 766,521 shares of the biotechnology company’s stock valued at $5,143,000 after purchasing an additional 666,696 shares during the period. Algert Global LLC grew its holdings in uniQure by 237.6% in the third quarter. Algert Global LLC now owns 414,241 shares of the biotechnology company’s stock valued at $2,780,000 after purchasing an additional 291,541 shares during the period. Jump Financial LLC purchased a new stake in uniQure in the third quarter valued at approximately $823,000. Swiss National Bank grew its holdings in uniQure by 8.0% in the third quarter. Swiss National Bank now owns 99,400 shares of the biotechnology company’s stock valued at $667,000 after purchasing an additional 7,400 shares during the period. Finally, Hudson Bay Capital Management LP grew its holdings in uniQure by 66.0% in the third quarter. Hudson Bay Capital Management LP now owns 390,200 shares of the biotechnology company’s stock valued at $2,618,000 after purchasing an additional 155,100 shares during the period. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Trading Down 0.8 %

QURE stock opened at $4.74 on Tuesday. uniQure has a one year low of $4.62 and a one year high of $22.48. The company has a debt-to-equity ratio of 0.49, a quick ratio of 8.68 and a current ratio of 8.85. The company has a fifty day moving average of $5.45 and a 200-day moving average of $6.10.

uniQure (NASDAQ:QURE) last released its earnings results on Wednesday, February 28th. The biotechnology company reported ($1.53) EPS for the quarter, topping the consensus estimate of ($1.54) by $0.01. uniQure had a negative net margin of 1,947.09% and a negative return on equity of 99.31%. The company had revenue of $6.69 million during the quarter, compared to analysts’ expectations of $3.20 million. Research analysts forecast that uniQure will post -4.49 EPS for the current year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.